Ritter Pharmaceuticals (RTTR) IPO Opens Flat

Today's IPO for Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) opened for trading at $5 after pricing its initial public offering of 4,000,000 shares of its common stock at a price to the public of $5 per share

Ritter Pharmaceuticals, Inc. has granted the underwriters a 45-day option to purchase up to 600,000 additional shares of common stock to cover over-allotments, if any.

Aegis Capital Corp. is acting as sole book-running manager for the offering. Chardan Capital Markets, LLC is acting as lead manager and Barrington Research is acting as co-manager for the offering.

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Ritter Pharma is advancing human gut health research by exploring the metabolic capacity of gut microbiota and translating the functionality of these microbiome modulators into safe and effective applications. Ritter Pharma’s lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.

You May Also Be Interested In

• UK’s EG Group reportedly files for US IPO worth about $1 billion
• Doncasters Group IPO expected to price at top of range
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal